Wednesday, November 13, 2024
HomeLatest Pharma-NewsMerck’s Checkpoint Inhibitor Keytruda (pembrolizumab) Hits Another Mark in Breast Cancer

Merck’s Checkpoint Inhibitor Keytruda (pembrolizumab) Hits Another Mark in Breast Cancer

Feb 12, 2020: Merck’s checkpoint inhibitor Keytruda (pembrolizumab) proved itself efficient in yet another cancer indication. The company announced positive results from the pivotal Phase III KEYNOTE-355 trial of the Keytruda in combination with chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors uttered PD-L1.

The trial met one of its twin primary endpoints, progression-free survival (PFS). An independent Data Monitoring Committee (DMC) performed interim review of the study, showing that first-line treatment with Keytruda with nab paclitaxel, paclitaxel orgemcitabine/ carboplatin had a statistically significant and clinically significant improvement in PFS relative to chemotherapy alone.

- Advertisement -

The DMC suggested the trial continue without changes in order to evaluate other dual primary endpoints, which is generally survival (OS).
KETNOYE 355 is a two part Phase III trial which is randomized.Part 1 was openlabel and
 lookedat Keytruda’s protection and tolerability in 30 patients with either nabpaclitaxel, paclitaxel, or gemcitabine/carboplatin.Part 2 was doubleblinded, with double primary OS and PFS endpoints in all participants as well as in participants whose tumours expressed PD-L1. Secondary endpoints comprise objective Response risk (ORR), response time(DOR),disease control rate(DCR), and health.

TNBC is a type of breast cancer which is particularly aggressive. Within the first five years after diagnosis, it has a high rate of recurrence. The triple-negative applies to negative tests of all three hormone receptors, oestrogen receptor, progesterone receptor and receptor of human epidermal growth factor 2 (HER2). Most cancer treatments target one or more of these hormone receptors, and this lack of all three makes the
cancer-targeting difficult for therapies. TNBC affects 15-20percent of women with breast cancer.
https://www.biospace.com/article/merck-s-checkpoint-inhibitor-keytruda-hits-another-mark-in-breast-cancer/



LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular